Amifostine Market Market Scope
Amifostine (Ethiofos) is a cytoprotective adjuvant utilized in malignancy chemotherapy and radiotherapy including DNA-restricting chemotherapeutic specialists. It is promoted by Clinigen under the business trademark Ethyol. Amifostine is supportive of medication which is actuated to the free thiol metabolite at the tissue site. The thiol metabolite is liable for the majority of the cytoprotective and radioprotective properties of amifostine and subsequently making the market to develop more in this season of the pandemic circumstance.
The market study is being classified by Type (400mg/Dose and 500mg/Dose), by Application (Ovarian Cancer Adjuvant Therapy, Head and Neck Cancer Adjuvant Therapy and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Research Analyst at AMA predicts that India Players will contribute to the maximum growth of Global Amifostine Market market throughout the predicted period.
Clinigen Group (United Kingdom), Sun Pharmaceutical (India), Taj Pharmaceuticals (India), Merro Pharmaceutical (China), Luye Pharma (China), Mingren Pharma (China), VHB Lifesciences Inc.(India) and Miracalus Pharma Private Limited (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Fulford India Ltd. (India) and Shantha Biotechnics Limited (India).
AdvanceMarketAnalytics has segmented the market of Global Amifostine Market market by Type, Application and Region.
On the basis of geography, the market of Amifostine Market has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
A radiation countermeasure that can be used prior to radiation exposure to protect the population from the harmful effects of radiation exposure remains a major unmet medical need and is recognized as an important area for research. Despite substantial advances in the research and development for finding non-toxic, safe, and effective prophylactic countermeasures for the acute radiation syndrome (ARS), no such agent has been approved by the United States Food and Drug Administration (FDA). Thus, the FDA has approved amifostine for limited clinical indications, but not for non-clinical uses.
- Adoption of new Chemicals in these Drugs
- Increasing Prevalence of Cancer Diseases Across the World is Rising the Market
- Cumulative Chemotherapy in Cancer Treatment is also Enhancing the Market
- Rising Healthcare Sector Across the World
- Growing Cancer Treatment with Specified Treatment Drugs
- Stringent Rules by the Government
- High Cost Associated with these Drugs
- Concern Related Towards the Side Effects
- Concern Related Towards the Allergies
Key Target AudienceManufacturers, Suppliers, Wholesalers, Distributors, and Retailers, Governmental bodies, and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase